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AbstrACt
Objective To evaluate if obstructive sleep apnoea (OSA) 
modifies the risk of coronary heart disease, type 2 
diabetes (T2D) and diabetic complications in a gender-
specific fashion.
Design and setting A longitudinal population-based study 
with up to 25-year follow-up data on 36 963 individuals 
(>500 000 person years) from three population-based 
cohorts: the FINRISK study, the Health 2000 Cohort Study 
and the Botnia Study.
Main outcome measures Incident coronary heart 
disease, diabetic kidney disease, T2D and all-cause 
mortality from the Finnish National Hospital Discharge 
Register and the Finnish National Causes-of-Death 
Register.
results After adjustments for age, sex, region, high-
density lipoprotein (HDL) and total cholesterol, current 
cigarette smoking, body mass index, hypertension, 
T2D baseline and family history of stroke or myocardial 
infarction, OSA increased the risk for coronary heart 
disease (HR=1.36, p=0.0014, 95% CI 1.12 to 1.64), 
particularly in women (HR=2.01, 95% CI 1.31 to 3.07, 
p=0.0012). T2D clustered with OSA independently of 
obesity (HR=1.48, 95% CI 1.26 to 1.73, p=9.11× 10−7
 ). The risk of diabetic kidney disease increased 1.75-fold 
in patients with OSA (95% CI 1.13 to 2.71, p=0.013). OSA 
increased the risk for coronary heart disease similarly 
among patients with T2D and in general population 
(HR=1.36). All-cause mortality was increased by OSA 
in diabetic individuals (HR=1.35, 95% CI 1.06 to 1.71, 
p=0.016).
Conclusion OSA is an independent risk factor for 
coronary heart disease, T2D and diabetic kidney disease. 
This effect is more pronounced even in women, who 
until now have received less attention in diagnosis and 
treatment of OSA than men.
IntrODuCtIOn  
Obstructive sleep apnoea (OSA) is a more 
common disorder than currently diag-
nosed in the clinic.1 It is a serious public 
health problem due to its many comorbidi-
ties, including an increased risk to coronary 
heart disease (CHD) and type 2 diabetes 
(T2D).2 3 The main known risk factors for 
OSA are obesity, male gender, high age, 
increased neck circumference and problems 
of upper airway or jaw anatomy.4–7 
Longitudinal studies have shown an 
association of OSA with incident or recur-
rent cardiovascular events and increased 
mortality.3 8 The risk of developing CHD is 
particularly increased in middle-aged men 
with OSA.9 10 Risk of CHD and mortality is 
usually increased if T2D is diagnosed before 
OSA.11
There is mounting evidence that OSA is 
an independent risk factor for the devel-
opment of T2D.2 12 13 Most of the available 
studies have been cross sectional,6 12 13 and 
not able to account for residual confounding 
factors.6 13 Other studies did not distinguish 
between type 1 diabetes (T1D) and T2D,14 
nor to generalise the results to the overall 
population.6 In some studies, this associa-
tion has been dispersed after adjustments for 
other risk factors.15
Also, studies investigating the synergistic 
effects of OSA and T2D on the progression of 
strengths and limitations of this study
 ► A large-scale population-based study of 36 963 indi-
viduals with up to 25 years of follow-up.
 ► Follow-up registers have excellent validity and 
coverage.
 ► Our study takes a large amount of confounding 
factors related to  obstructive sleep apnoea into 
consideration.
 ► Prospective study design should limit the risk of 
bias.
 ► Registry-based ascertainment through hospitalisa-
tion may miss non-hospitalised cases and treatment 
information.
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diabetic kidney disease are scarce and often limited by a 
cross-sectional design16–18 or small sample size.19
To explore the role of OSA for CHD, T2D and 
increased mortality, we conducted a large-scale popula-
tion-based study of 36 963 individuals with up to 25 years 
of follow-up. We specifically aimed at evaluating (1) if 
OSA modifies the risk of CHD and T2D independently 
of known risk factors like body mass index (BMI), blood 
pressure and lipids, (2) the role of OSA for the devel-
opment of diabetic complications including diabetic 
kidney disease and (3) examine if OSA has similar effects 
in women and men.
MethODs
study population
We included 36 963 participants in our study from 
national FINRISK Studies (FINRISK), Health 2000 
Cohort (H2000) and a subset of the Botnia and Preva-
lence, Prediction and Prevention of Diabetes (PPP)-
Botnia Studies (Botnia) including 1568 (4.2%) patients 
with OSA (ICD 10: G47.3, ICD 9: 3472A). Baseline char-
acteristics of the participants are presented in table 1.
Population-based FINRISK surveys are independent 
random samples drawn from the population register of 
six geographic areas of Finland (North Karelia, Kuopio, 
Lapland, Oulu, Turku/Loimaa and Helsinki/Vantaa) 
and stratified according to gender, 10-year age group and 
study area. The survey included a mailed questionnaire 
and a clinical examination at which a blood sample was 
drawn.20 Participants from different survey years (1992, 
1997, 2002 or 2007) were pooled together.
The total sample size for all FINRISK surveys was 29 257 
and participants who had missing information (n=7) 
or T1D (n=297) were excluded from the study. Thus, 
the total sample size was 28 953 where 13 792 male and 
15 161 female participants aged 24–74 years at baseline 
were included in the analyses. Of these participants, 1214 
(4.2%) had OSA.
The H2000 Study is a comprehensive combination of 
health interview and health examination survey. The 
study was based on a nationally representative sample of 
8028 persons aged ≥30 years living in mainland Finland.21 
After excluding participants who had missing informa-
tion (n=1331) or T1D (n=92), the final dataset consisted 
of 6605 participants, 2940 men and 3707 women. Out of 
this cohort 235 (3.6%) participants were diagnosed with 
OSA.
The Botnia Study was established in 1990 to investi-
gate familial clustering of diabetes in the Ostrobothnia 
region in western Finland, and the non-diabetic partic-
ipants have been prospectively followed.22 The popula-
tion-based PPP-Botnia Study was conducted in the same 
geographical area.23 From the Botnia/PPP Botnia Studies 
(referred to as Botnia Study), we included 1405 patients 
with T2D, 735 men and 670 women. In this cohort, 119 
participants (8.5%) had OSA diagnosis.
Patient and public involvement
Patients and public were not involved in the designing 
process of this study. The patients will not be informed 
individually of the study results otherwise than through 
possible media coverage.
Prospective follow-up and event definitions
During the follow-up of the study cohorts, data for hospi-
talisations and causes of death were obtained from the 
Finnish National Hospital Discharge Register and the 
Finnish National Causes-of-Death Register. These regis-
ters have excellent validity and coverage.24 25 Follow-up 
for FINRISK ended on 31 December 2014, for H2000 on 
31 December 2013 and for Botnia on 31 December 2015.
In the FINRISK cohorts, the follow-up was up to 22 
years (median 12.9 years, IQR 8.5–17.9) and in the H2000 
the follow-up was up to 14.5 years (median 13.9, IQR 
13.6–14.2). In the Botnia, the follow-up was up to 25 years 
(median 14.7 years, IQR 10.2–21.4). Altogether we had 
523 372 person years of follow-up.
OSA diagnosis is based on ICD codes which usually 
are based on subjective symptoms, clinical examina-
tion and sleep registration applying Apnoea–Hypopnea 
Index (number of apnoeas and hypopnoeas per hour of 
sleep)≥5.26 Incident CHD events were defined as the first 
occurrence of myocardial infarction, CHD death or coro-
nary revascularisation procedure at any time between 
the baseline examination and final follow-up date. Inci-
dent stroke events (STR), and diabetic kidney disease 
(including codes from ICD 10: N18, N19, E102, E112, 
ICD 9: 585, 2503A, 2503B and ICD8: 58200, 25004) were 
defined as the first occurrence of such event during this 
time period in hospital discharges or causes of deaths 
register. In FINRISK and H2000 cohorts, incident T2D 
was registered as the first occurrence of T2D in hospital 
discharges, causes-of-deaths register or entitlement to a 
reimbursed diabetes medication. Also, diabetes medica-
tion purchases were checked. If diabetic medication was 
the only evidence, at least three separate purchases were 
required. Persons with gestational or T1D were excluded 
from the analyses. In the Botnia Study, diabetes was 
defined based on a 75 g oral glucose tolerance test, with 
plasma glucose ≥7.0 mmol/L at fasting plasma glucose 
(FPG) or ≥11.1 mmol/L at 2 hours or previous diagnosis 
and use of antidiabetic medication.
ICD codes for each endpoint definition can be found 
in online supplementary table 1.
statistical methods
We tested associations between OSA and incident CHD 
events, diabetic kidney disease events and T2D using 
Cox proportional hazard models. Age at onset of OSA 
was used as a time-dependent covariate in our analyses 
and age was used as the timescale. In such Cox model, a 
person contributes in the model only for his/her at-risk 
period (ie, for a certain age range). During that period, 
he/she could become an OSA case, before the T2D diag-
nosis or cardiovascular event. In this case, using OSA as 
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a time-dependent covariate, he/she contributes to the 
model as a non-OSA case until the age at OSA diagnosis, 
and as an OSA case for the remaining of his/her at-risk 
period.27 Prevalent cases were excluded from the Cox 
regression analyses and the assumptions of the models 
were tested by  cox. zph—function.
In our FINRISK raw model for CHD, we used age, 
gender, geographical area and cohort year as covariates. 
In the adjusted model, we used, in addition to aforemen-
tioned factors, traditional risk factors as covariates for 
cardiovascular events: HDL, total cholesterol (CHOL), 
current cigarette smoking, BMI, hypertension (defined as 
a measured blood pressure of at least 140/90 mm Hg or 
the use of antihypertensive medications), prevalent T2D 
and family history of stroke or myocardial infarction.
In the raw analysis, similar to CHD, the association 
between OSA and T2D was adjusted for age, gender, 
geographical area and cohort year. In the adjusted model, 
we used also BMI as a covariate. Among patients with T2D 
with the endpoint of diabetic kidney disease, the model 
was adjusted for BMI and hypertension.
In the H2000, we were not able to adjust the model for 
family history of stroke or myocardial infarction because 
that information was not determined in the study. Other-
wise, the Cox time-dependent hazard model was adjusted 
for the same risk factors as mentioned before.
We combined the evidence from the FINRISK and 
H2000 to analyse CHD and T2D. To analyse T2D compli-
cations in more detail, we used the Botnia as a third 
cohort. The results were combined using fixed-effect 
meta-analysis.
Differences in baseline demographics and clinical char-
acteristics were tested using χ2 tests. Fisher’s exact test 
was used if the expected cell size was ≤5. For continuous 
variables, we used Student’s t-test (table 1). We consid-
ered p<0.05 as statistically significant, and all tests were 
two sided.
The R statistical package (V.3.2.5) was used for all anal-
yses (www. r- project. org).27
results
General results
To analyse the comorbidity of OSA and CHD, T2D 
outcomes and T2D complications, we combined longi-
tudinal data from three population-based cohorts 
including 36 963 participants with 1568 (4.2%) patients 
with OSA. These cohorts included FINRISK (n=28 953) 
with follow-up of up to 22 years (median 12.9 years, IQR 
8.5–17.9), H2000 (n=6605) with the median follow-up 
of 13.9 (IQR 13.6–14.2) and patients with T2D from the 
Botnia Study (n=1405) with the median follow-up of 15.3 
years (IQR 10.8–21.34). Altogether we had 6248 patients 
with T2D (16.9%).
We used the Finnish nationwide health registry data to 
construct diagnosis events. To evaluate the performance 
of the diagnostic events, we compared the main risk factor 
distributions between OSA cases and the rest of the popu-
lation. In figure 1, we show that BMI and systolic blood 
pressure are on average higher and HDL lower in the OSA 
group compared with the rest of the population. Table 1. 
presents a more thorough comparison of the groups.
Figure 1 (A) Distributions of age at obstructive sleep apnoea (OSA) diagnosis (mean 55.31 years) and (B) significant 
differences in body mass index (BMI) (p = 3.49×10−96), (C) systolic blood pressure (p = 7.78×10−3) and (D) HDL (p = 8.98×10−53 
among patients with OSA and non-OSA individuals in FINRISK.
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Cardiovascular outcomes
We first tested if OSA is associated with risk of incident 
CHD. In a model adjusted for age, sex and geographical 
region, OSA diagnosis elevates the risk of CHD (HR=1.54, 
95% CI 1.28 to 1.86, p=4.43× 10−6 ; table 2, online supple-
mentary figures 1,2).
When adjusting for CHD risk factors (age, sex, region, 
HDL and CHOL, current cigarette smoking, BMI, hyper-
tension, T2D baseline and family history of stroke or 
myocardial infarction), the HR attenuated to 1.36 (95% 
CI 1.12 to 1.64, p=1.40× 10−3 ). The estimates were similar 
across these cohorts and were slightly higher for women 
(adjusted HR=2.01, 95% CI 1.31 to 3.07, p=1.20× 10−3 
than for men (adjusted HR=1.25, 95% CI 1.01 to 1.54, 
p=0.039). OSA did not, however, associate with stroke risk 
(online supplementary table 2).
the effect of OsA on t2D and its complications
We next tested if OSA modifies the risk for T2D. Among 
patients with OSA, this risk was elevated (HR=2.52, 
p=1.91× 10−32 , 95% CI 2.16 to 2.93). After further adjust-
ment for BMI, the risk remained at 1.48-fold (p=9.11× 10−7,  
95% CI 1.26 to 1.73) showing a similar effect in both cohorts 
(online supplementary figures 2,3). Again, the effect was 
more prominent in women (adjusted HR = 1.63, 95% CI 
1.20 to 2.23, p=2.20× 10−3 ) than in men (HR = 1.44, 95% CI 
1.27 to 2.21, p=9.62× 10−5 ) (table 3).
To analyse T2D complications more in detail, we 
included the Botnia cohort into the meta-analysis. H2000 
lacked incident diabetic kidney disease events among 
patients with OSA.
Among patients with T2D, OSA elevated the risk for 
diabetic kidney disease (HR=2.16, 95% CI 1.40 to 3.34, 
p=5.00× 10−4 ; table 4).
When adjusted for the known risk factors for diabetic 
kidney disease (BMI and hypertension), the HR was slightly 
reduced to 1.75 (95% CI 1.13 to 2.71, p=0.013, online 
supplementary figures 4,5). The effects were similar in both 
cohorts.
Among patients with T2D, OSA alone increased the 
risk for CHD by 1.40 (95% CI 1.10 to 1.81, p=8.50× 10−3
 ; table 4). This was almost unaffected by adding the 
following risk factors: HDL and CHOL, current cigarette 
smoking, BMI, hypertension and family history of stroke 
or myocardial infarction (HR=1.36, 95% CI 1.05 to 1.76, 
p=0.019, online supplementary figures 4,5).
the effect of OsA to mortality risk
We also examined whether OSA was an independent risk 
factor for all-cause mortality. OSA increased the risk in the 
raw model (HR=1.18, 95% CI 1.00 to 1.40, p = 0.057) and 
this risk attenuated after adjustment for other risk factors. 
Among T2D individuals, OSA increased the all-cause 
mortality risk in the raw model (HR=1.40, 95% CI 1.21 to 
1.62, p=2.03× 10−6 ) and after adjustments (HR=1.35, 95% CI 
1.06 to 1.71, p=0.016; table 5, online supplementary figure 
6).
DIsCussIOn
Our results from three prospective population-based 
cohorts found a severe impact of OSA on cardiovascular 
health, T2D and mortality during a life course. We demon-
strate that OSA is an independent risk factor for CHD and 
Table 2 HRs between individuals with obstructive sleep apnoea and the population for incident coronary heart disease events
Number of events/
subjects at risk
Raw model Adjusted model
HR (95% CI) P values HR (95% CI) P values
FINRISK 2129/27 948 1.43 (1.17 to 1.75) 7.34× 10−4 1.25 (1.01 to 1.54) 0.037
H2000 565/6267 2.13 (1.40 to 3.24) 4.08× 10−4 1.91 (1.25 to 2.92) 2.80× 10−3 
Combined 2694/34 215 1.54 (1.28 to 1.86) 4.43× 10−6 1.36 (1.12 to 1.64) 1.40× 10−3 
Men
  FINRISK 1480/13 066 1.33 (1.06 to 1.67) 0.015 1.18 (0.94 to 1.49) 0.157
  H2000 306/2748 1.81 (1.13 to 2.91) 0.014 1.57 (0.97 to 2.55) 0.069
  Combined 1786/15 814 1.41 (1.15 to 1.73) 1.10× 10−3 1.25 (1.01 to 1.54) 0.039
Women
  FINRISK 649/14 882 1.99 (1.24 to 3.19) 4.11× 10−4 1.66 (1.03 to 2.68) 0.036
  H2000 259/3519 4.12 (1.68 to 10.18) 2.06× 10−3 4.03 (1.62 to 10.01) 2.64× 10−3 
  Combined 908/18 401 2.33 (1.53 to 3.53) 7.19× 10−5 2.01 (1.31 to 3.07) 1.20× 10−3 
The FINRISK raw model is adjusted for age, cohort year, geographical area and gender. The adjusted model is adjusted for HDL and total 
cholesterol, current cigarette smoking, body mass index (BMI), hypertension, prevalent type 2 diabetes and family history of stroke or 
myocardial infarction in addition to covariates of the raw model. The Health 2000 Cohort (H2000) raw model is adjusted for geographical area 
and gender. H2000-adjusted model is adjusted for HDL and total cholesterol, current cigarette smoking, BMI, hypertension and prevalent type 
2 diabetes in addition to covariates of the raw model.
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T2D in the general population. Using a combination of 
population cohorts and a T2D cohort, Botnia, we present 
evidence for the role of OSA in the risk of T2D complica-
tions. To our knowledge, this is the largest study of the role 
of OSA in CHD and T2D diseases, combining sample size 
of over 36 000 individuals with up to 20+ years of follow-up.
These results allow us to draw several conclusions. First, 
our results illustrate that nationwide health registry data 
can successfully be used to identify cases of OSA. Second, 
the registry-based OSA cases revealed an increased risk 
for future CHD events and T2D. This risk was surprisingly 
high in women, even after adjusting for risk factors, shed-
ding new light to the potential sex differences in OSA. 
This finding may provide tools to identify particularly 
women in high risk of CHD and T2D. Third, we observed 
convincing evidence indicating that T2D accumulated to 
patients with OSA independent of obesity.
OSA seems to increase the risk for CHD to the same 
extent in diabetic and non-diabetic individuals but the risk 
of diabetic kidney disease was 75% higher among patients 
with OSA compared with diabetic individuals without OSA 
diagnosis. All-cause mortality was increased by OSA among 
Table 3 HRs between individuals with obstructive sleep apnoea and the population for incident type 2 diabetes
Number of events/
subjects at risk
Raw model Adjusted model
HR (95% CI) P values HR (95% CI) P values
FINRISK 2435/27 161 2.40 (2.03 to 2.84) 1.53× 10−24 1.38 (1.16 to 1.64) 2.74× 10−4 
H2000 455/6181 3.18 (2.20 to 4.59) 7.03× 10−10 2.05 (1.42 to 2.97) 1.41× 10−4 
Combined 2890/33 342 2.52 (2.16 to 2.93) 1.91× 10−32 1.48 (1.26 to 1.73) 9.11× 10−7 
Men
  FINRISK 1372/12 880 2.21 (1.81 to 2.69) 2.55× 10−15 1.28 (1.05 to 1.57) 0.017
  H2000 257/2772 3.65 (2.44 to 5.44) 2.23× 10−10 2.27 (1.51 to 3.41) 8.08× 10−5 
  Combined 1629/15 652 2.43 (2.04 to 2.90) 4.16× 10−23 1.44 (1.27 to 2.21) 9.62× 10−5 
Women
  FINRISK 1063/14 281 3.14 (2.28 to 4.33) 3.12× 10−12 1.65 (1.18 to 2.29) 2.98× 10−3 
  H2000 198/3409 2.16 (0.80 to 5.87) 0.13 1.48 (0.55 to 4.02) 0.44
  Combined 1261/17 690 3.03 (2.23 to 4.12) 1.25× 10−15 1.63 (1.20 to 2.23) 2.20× 10−3 
The FINRISK raw model is adjusted for age, cohort year, geographical area and gender. The adjusted model is adjusted for body mass index 
(BMI) in addition to covariates of the raw model. The Health 2000 Cohort (H2000) raw model is adjusted for geographical area and gender. 
The adjusted model is adjusted for BMI in addition to covariates of the raw model.
Table 4 HRs for type 2 diabetes complications
Number of events/
subjects at risk
Raw model Adjusted model
HR (95% CI) P values HR (95% CI) P values
DKD 
  FINRISK 147/3932 2.15 (1.27 to 3.62) 4.10× 10−3 1.72 (1.01 to 2.93) 0.044
  Botnia 91/1380 2.19 (1.003 to 4.79) 0.049 1.80 (0.82 to 3.96) 0.143
  Combined 238/5312 2.16 (1.40 to 3.34) 5.00× 10−4 1.75 (1.13 to 2.71) 0.013
CHD 
  FINRISK 640/3710 1.44 (1.07 to 1.95) 0.016 1.40 (1.04 to 1.90) 0.028
  H2000 152/761 1.46 (0.74 to 2.82) 0.272 1.46 (0.74 to 2.89) 0.274
  Botnia 236/1253 1.18 (0.60 to 2.31) 0.630 1.07 (0.54 to 2.11) 0.840
  Combined 1028/5724 1.40 (1.10 to 1.81) 8.50× 10−3 1.36 (1.05 to 1.76) 0.019
The FINRISK raw models are adjusted for age, cohort year, geographical area and gender. The Health 2000 Cohort (H2000) raw models 
are adjusted for age, geographical area and gender. The Botnia raw models are adjusted for age and gender. The adjusted models for 
diabetic kidney disease (DKD) are adjusted for body mass index (BMI) and hypertension in all cohorts in addition to covariates of the raw 
model. The FINRISK-adjusted model for coronary heart disease (CHD) is adjusted for HDL and total cholesterol, current cigarette smoking, 
BMI, hypertension and family history of stroke or myocardial infarction in addition to covariates of the raw model. The H2000-adjusted and 
Botnia-adjusted models for CHD are adjusted for HDL and total cholesterol, current cigarette smoking, BMI and hypertension in addition to 
covariates of the raw model.
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patients with T2D but not significantly in the general 
population. The main cause of mortality was CHD both in 
diabetics (33.8%) and in the general population (30.8%).
While previous studies mostly lacked the longitudinal 
dimension, also our study has limitations: (1) regis-
try-based ascertainment through hospitalisation may miss 
non-hospitalised cases (false negatives) and (2) treatment 
information such as Continuous Positive Airway Pressure 
(CPAP) compliance and (3) OSA severity, emphasising 
more severe OSA cases affecting the hazard estimates. 
However, in spite of these limitations, the study design 
provides comprehensive estimates of the adverse effects 
of OSA on CHD and T2D disorders. This is supported by 
a recent meta-analysis reporting an risk ratio (RR) of 1.49 
for the association of OSA and T2D,28 which is well in line 
with the results from our study.
It is being increasingly recognised that OSA can accelerate 
loss of kidney function,29 but OSA usually presents with other 
risk factors of kidney function like obesity, T2D and hyper-
tension.30 31 It has been hypothesised that there is a bidirec-
tional relationship between OSA and kidney disease, where 
kidney disease promotes OSA and OSA kidney disease.29 
Our study supports the latter hypothesis that in patients with 
diabetes OSA increased the risk for kidney disease by 1.75-
fold after the adjustment for other risk factors. This is in line 
with previous, smaller studies.19 29
An important advantage of our large sample size was that 
we could investigate gender differences in the CHD and T2D 
risk associated with OSA. While we did not observe a signifi-
cantly higher risk in women than in men, our data opposite 
to previous studies clearly show that the severe outcome of 
OSA is as severe in women as in men (if not more severe).3 32 
It is possible explanation for this finding may be delayed 
diagnosis of OSA in women compared with men.
Taken together, our longitudinal study with up to 
523 372 person years of follow-up demonstrates that OSA 
is an independent risk factor for CHD and T2D and mark-
edly increase risk for diabetic kidney disease. This empha-
sises the need to search for signs of OSA in patients with 
T2D with rapid progression of T2D and evaluate whether 
this progression can be halted by CPAP therapy.
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